uPAR-uPA-PAI-l interactions and signaling: A vascular biologist's view

被引：209

作者：

Binder, Bernd R. ^{[1
]}

Mihaly, Judit ^{[1
]}

Prager, Gerald W. ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, Ctr Biomol Med & Pharmacol, A-1090 Vienna, Austria

来源：

THROMBOSIS AND HAEMOSTASIS | 2007年 / 97卷 / 03期

关键词：

urokinase/receptor; plasminogen activator inhibitors; angiogenesis and inhibitors; atherosclerosis; restenosis;

D O I：

10.1160/TH06-11-0669

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

The urokinase-type plasminogen activator (uPA), its inhibitor PAI-I and its cellular receptor (uPAR), play a pivotal role in pericellular proteolysis. In addition, through their interactions with extracellular matrix proteins as well as with transmembrane receptors and other links to the intracellular signaling machinery, they modulate cell migration, cell-matrix interactions and signaling pathways. A large body of experimental evidence from invitro and in-vivo data as well as from the clinics indicates an important role of the uPA-uPAR-PAI-I systems in cancer. In addition to their role in tumor cell biology, the uPA-uPAR-PAI-I systems are also important for vascular biology by modulating angiogenesis and by altering migration of smooth muscle cells and fibrin deposition in atherosclerosis and restenosis. This review will focus on the general mechanism of uPAR/uPA/PAI-I interactions and signaling and the possible relevance of this system in vascular biology.

引用

收藏

页码：336 / 342

页数：7

相关论文

共 119 条

[1]

Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo [J].

Aguirre-Ghiso, JA ;

Liu, D ;

Mignatti, A ;

Kovalski, K ;

Ossowski, L .

MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) :863-879

[2]

Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684

[3]

ASSELBERGS FW, 2006, J THROMB HAEMOST

[4]

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].

Bajou, K ;

Masson, V ;

Gerard, RD ;

Schmitt, PM ;

Albert, V ;

Praus, M ;

Lund, LR ;

Frandsen, TL ;

Brunner, N ;

Dano, K ;

Fusenig, NE ;

Weidle, U ;

Carmeliet, G ;

Loskutoff, D ;

Collen, D ;

Carmeliet, P ;

Foidart, JM ;

Noël, AS .

JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784

[5]

Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth [J].

Bajou, K ;

Maillard, C ;

Jost, M ;

Lijnen, HR ;

Gils, A ;

Declerck, P ;

Carmeliet, P ;

Foidart, JM ;

Noel, A .

ONCOGENE, 2004, 23 (41) :6986-6990

[6]

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].

Bajou, K ;

Noël, A ;

Gerard, RD ;

Masson, V ;

Brunner, N ;

Holst-Hansen, C ;

Skobe, M ;

Fusenig, NE ;

Carmeliet, P ;

Collen, D ;

Foidart, JM .

NATURE MEDICINE, 1998, 4 (08) :923-928

[7]

Structural basis of interaction between urokinase-type plasminogen activator and its receptor [J].

Barinka, Cyril ;

Parry, Graham ;

Callahan, Jennifer ;

Shaw, David E. ;

Kuo, Alice ;

Bdeir, Khalil ;

Cines, Douglas B. ;

Mazar, Andrew ;

Lubkowski, Jacek .

JOURNAL OF MOLECULAR BIOLOGY, 2006, 363 (02) :482-495

[8]

Regulation of urokinase receptor proteolytic function by the tetraspanin CD82 [J].

Bass, R ;

Werner, F ;

Odintsova, E ;

Sugiura, T ;

Berditchevski, F ;

Ellis, V .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (15) :14811-14818

[9]

uPAR: A versatile signalling orchestrator [J].

Blasi, F ;

Carmeliet, P .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) :932-943

[10]

UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR, BETA-2-INTEGRINS, AND SRC-KINASES WITHIN A SINGLE RECEPTOR COMPLEX OF HUMAN MONOCYTES [J].

BOHUSLAV, J ;

HOREJSI, V ;

HANSMANN, C ;

STOCKL, J ;

WEIDLE, UH ;

MAJDIC, O ;

BARTKE, I ;

KNAPP, W ;

STOCKINGER, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (04) :1381-1390

← 1 2 3 4 5 6 7 8 9 10 →